900 reports of this reaction
5.7% of all FAM TRASTUZUMAB DERUXTECAN NXKI reports
#3 most reported adverse reaction
DISEASE PROGRESSION is the #3 most commonly reported adverse reaction for FAM TRASTUZUMAB DERUXTECAN NXKI, manufactured by Daiichi Sankyo Inc.. There are 900 FDA adverse event reports linking FAM TRASTUZUMAB DERUXTECAN NXKI to DISEASE PROGRESSION. This represents approximately 5.7% of all 15,771 adverse event reports for this drug.
Patients taking FAM TRASTUZUMAB DERUXTECAN NXKI who experience disease progression should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DISEASE PROGRESSION is moderately reported among FAM TRASTUZUMAB DERUXTECAN NXKI users, representing a notable but not dominant share of adverse events.
In addition to disease progression, the following adverse reactions have been reported for FAM TRASTUZUMAB DERUXTECAN NXKI:
The following drugs have also been linked to disease progression in FDA adverse event reports:
DISEASE PROGRESSION has been reported as an adverse event in 900 FDA reports for FAM TRASTUZUMAB DERUXTECAN NXKI. This does not prove causation, but indicates an association observed in post-market surveillance data.
DISEASE PROGRESSION accounts for approximately 5.7% of all adverse event reports for FAM TRASTUZUMAB DERUXTECAN NXKI, making it one of the most commonly reported side effect.
If you experience disease progression while taking FAM TRASTUZUMAB DERUXTECAN NXKI, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.